Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$106.45 USD

106.45
1,174,113

-0.63 (-0.59%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $107.09 +0.64 (0.60%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus

by Zacks Equity Research

NKTR reports encouraging third-quarter results as both earnings and revenues beat estimates. Product sales increase year over year.

Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus

by Zacks Equity Research

IMVT reports dismal second-quarter fiscal 2025 results. It is on track to initiate several studies on IMVT-1402 across various autoimmune indications.

Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus

by Zacks Equity Research

IONS reports better-than-expected top and bottom-line numbers for the third quarter of 2024.

CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up

by Zacks Equity Research

Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales. Management raises sales guidance.

Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth

by Zacks Equity Research

PCRX reports mixed third-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.

Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth

by Zacks Equity Research

ACAD reports encouraging third-quarter results as earnings and revenues beat estimates. Nuplazid and Daybue sales record year-over-year growth.

NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View

by Zacks Equity Research

Novo Nordisk reports lower-than-expected Q3 results, missing both earnings and revenue estimates. Management updates 2024 financial guidance.

Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates

by Zacks Equity Research

RARE reports encouraging third-quarter results, beating earnings and revenue estimates. Product sales increase year over year.

Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y

by Zacks Equity Research

EDIT reports mixed third-quarter 2024 results as earnings beat expectations while revenues miss the same.

Is Novartis (NVS) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how argenex SE (ARGX) and Novartis (NVS) have performed compared to their sector so far this year.

Zoetis Q3 Earnings & Revenues Beat, '24 Outlook Raised, Stock Up

by Zacks Equity Research

ZTS stock gains as third-quarter results beat both earnings and revenue estimates, driven by strong product sales. Management raises the 2024 outlook.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus

by Kinjel Shah

LLY, MRK, PFE, ABBV and NVS announce report third-quarter results.

Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up

by Zacks Equity Research

MDGL stock is up as the company reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.

Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down

by Zacks Equity Research

ALNY's Q3 loss per share matches the Zacks Consensus Estimate and revenues miss the same due to lower collaboration revenues. The stock falls 5.3%.

REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales

by Zacks Equity Research

Regeneron reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Eylea HD, Dupixent and Libtayo sales.

BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up

by Zacks Equity Research

Blueprint stock gains from better-than-expected third-quarter results, driven by robust Ayvakit sales growth. The company raises revenue guidance for 2024.

Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks

by Zacks Equity Research

Eli Lilly misses third-quarter estimates for earnings and sales. Mounjaro and Zepbound sales also miss estimates. Stock declines 11%.

BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance Raised

by Zacks Equity Research

BMRN reports better-than-expected third-quarter results, beating both earnings and sales estimates. Management raises 2024 guidance.

ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales

by Zacks Equity Research

Intra-Cellular reports mixed third-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.

Why Novartis (NVS) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales

by Zacks Equity Research

Incyte reports mixed third-quarter results as earnings miss estimates while revenues beat the same due to increased sales of Jakafi and Opzelura.

Novartis Beats on Q3 Earnings and Sales, Raises 2024 Outlook

by Zacks Equity Research

NVS' third-quarter earnings and sales beat estimates. Based on the strong momentum of key drugs, the company raises its outlook for 2024.

Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Novartis (NVS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

The Zacks Analyst Blog Novartis, Reddit and Check Point Software Technologies

by Zacks Equity Research

Novartis, Reddit and Check Point Software Technologies are included in this Analyst Blog.